文献速递白血病

靶向IL-1/IRAK1/4信号通路清除急性髓系白血病干细胞

Targeting IL-1/IRAK1/4 signaling in acute myeloid leukemia stem cells following treatment and relapse.
PubMed 文献 · Leukemia · 2025-12-19

该研究对诊断时和复发时功能定义的急性髓系白血病干细胞进行转录组分析,发现IL-1信号通路显著改变,IL1R1和IL1RAP在白血病干/祖细胞中上调。敲低IL1R1/IL1RAP可降低原代AML细胞的克隆形成和/或植入能力,Il1r1敲除可降低MLL-AF9小鼠LSC频率并延长生存。研究者开发了新型IRAK1/4抑制剂UR241-2,可抑制IL-1/IRAK1/4信号并选择性抑制诊断和复发时LSC克隆形成,同时不伤害正常造血干/祖细胞。

要点

  • IL1R1和IL1RAP在诊断和复发时的白血病干/祖细胞中上调。
  • 敲低IL1R1/IL1RAP降低原代AML细胞克隆形成和/或植入。
  • UR241-2选择性抑制LSC克隆形成且不伤害正常造血干/祖细胞。

核心结论

  • 靶向IL-1/IRAK1/4信号通路(如UR241-2)具有清除LSC、改善AML疗效的治疗潜力。

研究设计与样本

  • 对诊断时和复发时功能定义的LSC群体进行转录组分析。
  • 使用原代人类AML细胞进行敲低和克隆形成/植入实验。
  • 使用MLL-AF9白血病小鼠进行Il1r1敲除实验。
  • 开发并测试新型IRAK1/4抑制剂UR241-2。

主要发现

  • 诊断和复发时LSC中IL-1信号通路显著改变,IL1R1和IL1RAP在白血病干/祖细胞中上调。
  • 敲低IL1R1和IL1RAP降低原代人类AML细胞的克隆形成和/或植入。
  • Il1r1敲除降低MLL-AF9小鼠LSC频率并延长生存。
  • UR241-2抑制IL-1刺激后的NF-κB激活及p65和p38磷酸化。
  • UR241-2选择性抑制诊断和复发时原代人类AML细胞的LSC克隆形成,不伤害正常造血干/祖细胞,并降低白血病小鼠AML植入。

临床怎么用

  • UR241-2可能作为靶向LSC的治疗策略用于AML诊断和复发阶段。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Therapies for acute myeloid leukemia (AML) face formidable challenges due to relapse, often driven by leukemia stem cells (LSCs). Strategies targeting LSCs hold promise for enhancing outcomes, yet paired comparisons of functionally defined LSCs at diagnosis and relapse remain underexplored. We present transcriptome analyses of functionally defined LSC populations at diagnosis and relapse, revealing significant alterations in IL-1 signaling. Interleukin-1 receptor type I (IL1R1) and interleukin-1 receptor accessory protein (IL1RAP) were notably upregulated in leukemia stem and progenitor cells at both diagnosis and relapse. Knockdown of IL1R1 and IL1RAP reduced the clonogenicity and/or engraftment of primary human AML cells. In leukemic MLL-AF9 mice, Il1r1 knockout reduced LSC frequency and extended survival. To target IL-1 signaling at both diagnosis and relapse, we developed UR241-2, a novel interleukin-1 receptor-associated kinase 1 and 4 (IRAK1/4) inhibitor. UR241-2 robustly suppressed IL-1/IRAK1/4 signaling, including NF-κB activation and phosphorylation of p65 and p38, following IL-1 stimulation. UR241-2 selectively inhibited LSC clonogenicity in primary human AML cells at both diagnosis and relapse, while sparing normal hematopoietic stem and progenitor cells. It also reduced AML engraftment in leukemic mice. Our findings highlight the therapeutic potential of UR241-2 in targeting IL-1/IRAK1/4 signaling to eradicate LSCs and improve AML outcomes.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Ho TC, LaMere MW, Kawano H, et al. Targeting IL-1/IRAK1/4 signaling in acute myeloid leukemia stem cells following treatment and relapse. Leukemia. 2025. PMID: 41419607. doi:10.1038/s41375-025-02816-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。